Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Group A Streptococcus (GAS) M protein is the primary surface-anchored virulence factor of Streptococcus pyogenes (UniProt, 2024). The N-terminal region of this protein is highly hypervariable and defines the emm type of the strain, serving as the primary target for protective, type-specific antibodies (Smeesters, P. R., et al., 2010). Biologically, the N-terminus facilitates immune evasion by binding host proteins such as fibrinogen and complement regulators like Factor H, which inhibits opsonophagocytosis (Cunningham, M. W., 2000). Because it is a potent immunogen, it is a central focus for vaccine development, including multivalent candidates like StreptAnova (Dale, J. B., et al., 2016). However, a significant challenge in targeting this region is its potential for molecular mimicry with human tissue proteins, which can trigger autoimmune sequelae such as rheumatic heart disease (Cunningham, M. W., 2000). Current therapeutic strategies aim to overcome this by using complex mixtures of N-terminal peptides to provide broad coverage across the numerous GAS serotypes (Dale, J. B., et al., 2016).
Induction of type-specific opsonophagocytic antibodies that neutralize the bacteria and prevent host cell colonization by targeting the hypervariable N-terminal epitopes.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Group A Streptococcus M protein N-terminal region (M protein HVR).